Viking Therapeutics Presents New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The Digital International Liver Congress�
Go back to Viking Therapeutics Presents New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The Digital International Liver Congress�| ING Van Kampen Equity Growth Fund S 2 Class (NASDAQ: VKTX) | Delayed: 63.42 -1.25 (1.93%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $64.67 | 52 Week High | $5.17 | |||
| Open | $64.54 | 52 Week Low | $0.94 | |||
| Day High | $65.80 | P/E | N/A | |||
| Day Low | $61.64 | EPS | $0.00 | |||
| Volume | 3,046,026 | |||||
